Botulinum Antitoxin Heptavalent (2026)

The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Botulinum Antitoxin Heptavalent (HBAT) through this Request for Information (RFI), in accordance with the Procurement Act 2023.